Senetek Initiates Clinical Trials of Pyratine 6 for Acne Rosacea

Senetek PLC (OTCBB: SNTKY), a life sciences product development
company targeting the science of aging, has initiated clinical trials
of its Pyratine 6 compound (PRK 124) for Acne Rosacea after evaluating
positive results from a comparison of separate clinical trials of
Pyratine 6 and Kinetin, Senetek's original anti-aging active
ingredient.

An independent comparative analysis evaluated the effectiveness of
Senetek's second-generation patented cytokinin, Pyratine 6 (PRK 124)
relative to its original anti-aging active ingredient, Kinetin. The
analysis compared results of separate clinical studies conducted at
the University of California, Irvine (Kinetin) and at the independent
research laboratory RCTS, Inc. in Irving, Texas (Pyratine 6). The
subjects in the Pyratine 6 clinical trial scored significantly higher
on each measure than those in the Kinetin study throughout the 12
weeks of evaluation. In some measures the comparison was particularly
notable, such as fine wrinkles (22% improvement with Pyratine 6 vs. 2%
improvement with Kinetin after eight weeks), skin roughness (86%
improvement with Pyratine 6 vs. 35% improvement with Kinetin after
eight weeks) and overall skin aging (24% vs. 3% after eight weeks).

The Pyratine 6 study also featured additional evaluative
methodologies not included in the Kinetin study, such as the NOVA
Dermal Phase Meter for measuring the skin's moisture content, and
expert evaluations of reductions in erythema (redness) and acne
lesions. The NOVA apparatus measured increases in skin moisture
content of 35% and 41% after eight and twelve weeks, respectively. The
evaluations found 42% and 62% reductions in erythema after two and
four weeks, respectively, and a 45% reduction in acne lesions after
twelve weeks. Pyratine 6 was well tolerated by all subjects, producing
no measurable skin irritation or signs of allergic contact dermatitis
with twice-daily application over the 12 week study period.

Frank Massino, Chief Executive Officer of Senetek commented, "The
data collected through the comparative analysis of Pyratine 6 and
Kinetin has given us significant reason to focus our efforts on taking
the strategic steps necessary to launch Pyratine 6 commercially as an
anti-aging compound as well as initiate clinical trials to prove that
Pyratine 6 can also be used as an effective treatment for Acne
Rosacea. Following our success with Kinetin, we are excited about the
potential for Pyratine 6 as it presents yet another valuable
opportunity for our Company."

Enrollment has begun on the new Senetek sponsored Institutional
Review Board (IRB)-approved pilot clinical study of Pyratine 6 for
treatment of Rosacea, to be conducted at the University of California
at Irvine. The comparative analysis results also have influenced one
of the Company's prospective licensees, a major cosmetic company, to
commence separate clinical trials of Pyratine 6 for Acne Rosacea and
for skin whitening.

Acne Rosacea is a common chronic dermatosis characterized by
inflammatory lesions and persistent erythema (redness) conservatively
estimated to afflict some 16 million people in the U.S. and 45 million
people worldwide. Acne Rosacea is currently primarily treated with
oral antibiotics such as tetracycline and erythromycin and topical
antibiotics such as metronidazole, which involve long-term
tolerability and other health concerns.

About Senetek PLC

Senetek is a life sciences-driven product development and
licensing company with a portfolio of intellectual properties
targeting the science of aging, including skincare and dermatological
therapeutics, erectile dysfunction and nutrition. Senetek holds
patents on the use of Kinetin and its analog Zeatin, naturally
occurring cytokinins that have proven effective in improving the
appearance of aging skin with virtually none of the side effects
associated with acid-based active ingredients, which it has licensed
to Valeant Pharmaceuticals International, and on a number of second
generation cytokinins and other plant-derived compounds. Senetek's
researchers at the University of Aarhus in Denmark also are
collaborating with a broad range of academic and government-based
research enterprises, including The Institute of Experimental Botany
of the Czech Academy of Sciences, and with the Department of
Dermatology, University of California at Irvine, to identify and
evaluate additional new biologically active compounds for this high
growth field. In addition, Senetek has entered into exclusive licenses
for Europe and North America, respectively, for its patented
combination drug treatment for erectile dysfunction, Invicorp(R), has
an exclusive manufacturing distributorship for its proprietary
diagnostic monoclonal antibodies, and recently sold, with retained
rights of profit participation, its patented drug delivery system,
Reliaject(R).

Visit Senetek PLC's Web site at http://www.senetekplc.com.

Safe Harbor Statement

This news release contains statements that may be considered
'forward-looking statements' within the meaning of the Private
Securities Litigation Reform Act, including those that might imply
commercial potential and successful evaluation and development of new
compounds. Forward-looking statements by their nature involve
substantial uncertainty, and actual results may differ materially from
those that might be suggested by such statements. Important factors
identified by the Company that it believes could result in such
material differences are described in the Company's Annual Report on
Form 10-K/A for the year 2005. However, the Company necessarily can
give no assurance that it has identified or will identify all of the
factors that may result in any particular forward-looking statement
materially differing from actual results, and the Company assumes no
obligation to correct or update any forward-looking statements which
may prove to be inaccurate, whether as a result of new information,
future events or otherwise.